BMS‐986122
BMS‐986122 is a selective positive allosteric modulator (PAM) of the μ-opioid receptor (MOR).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BMS‐986122 is a selective positive allosteric modulator (PAM) of the μ-opioid receptor (MOR). MOR PAMs like BMS-986122 could be useful as novel analgesics with reduced side effects compared to conventional opioid analgesics. However, the potential specifically of BMS-986121 and BMS-986122 as pharmaceutical drugs may be restricted due to their complex synthesis.
Pharmacodynamics
BMS-986122 can enhance the affinity and efficacy of various orthosteric MOR agonists, including the endogenous opioid peptides, for the MOR. However, its effects are dependent on the ligand, and in the case of morphine, it enhances efficacy without affecting affinity. BMS‐986122 has no MOR agonist activity, is selective for the MOR, and lacks PAM activity at the δ-opioid receptor (DOR).
However, it has been identified as a silent allosteric modulator (SAM) of the DOR and κ-opioid receptor (KOR). The drug has analgesic effects in animals. In contrast to MOR agonists, BMS-986122 does not appear to promote opioid-induced constipation, respiratory depression, or reward.
The drug has been found to attenuate opioid tolerance in rodents, specifically in terms of analgesia. Besides its analgesic effects, BMS-986122 has been found to enhance the analgesic effects of non-opioid analgesics such as clonidine and gabapentin in rodents.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1369636209 under CC BY-SA 4.0; modifications have been made.